On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
-
BUSINESS Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
-
ACADEMIA Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
-
BUSINESS Daiichi Sankyo Cuts FY2025 Profit Outlook on ADC Supply Plan Review
May 11, 2026
-
BUSINESS J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
May 8, 2026
-
REGULATORY Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
-
BUSINESS Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
-
REGULATORY MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
-
REGULATORY Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
-
BUSINESS Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
-
REGULATORY Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
-
BUSINESS Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
-
BUSINESS Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
-
BUSINESS Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
-
REGULATORY Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
-
BUSINESS Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
-
BUSINESS Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
-
ORGANIZATION PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
-
BUSINESS Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
-
REGULATORY Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…